The genetics of motor neuron diseases

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 4, Issue 4, 2003, Pages 225-231

  Figlewicz, Denise A ^a   Orrell, Richard W ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

ALS; Genetics; Motor neuron diseases; Spinal muscular atrophy; Spinobulbar neuronopathy

Indexed keywords

ADENINE; ALPHA TOCOPHEROL; ANDROGEN RECEPTOR; ASCORBIC ACID; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BETA N ACETYLHEXOSAMINIDASE; CASPASE INHIBITOR; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; CYTOCHROME C OXIDASE; CYTOSINE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; GABAPENTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GUANINE; GUANOSINE TRIPHOSPHATASE; LYSINE ACETYLSALICYLATE; NEUROTROPHIN; PENICILLAMINE; POLYGLUTAMINE; POLYPEPTIDE; PROTEIN P44; PROTEOLIPID PROTEIN; RILUZOLE; SPASTIN; TRIENTINE; UNINDEXED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CHROMOSOME 15Q; CHROMOSOME 16Q; CHROMOSOME 18Q; CHROMOSOME 20P; CHROMOSOME 2Q; CHROMOSOME 9Q; DISEASE CLASSIFICATION; GENE MUTATION; GENETIC ANALYSIS; GM2 GANGLIOSIDOSIS; HUMAN; KENNEDY DISEASE; MOTOR NEURON DISEASE; MOUSE; NONHUMAN; PATHOGENESIS; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; REVIEW; SPASTIC PARAPLEGIA; SPINAL MUSCULAR ATROPHY; TRINUCLEOTIDE REPEAT; X CHROMOSOME LINKAGE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; GANGLIOSIDOSES, GM2; HEREDITARY MOTOR AND SENSORY NEUROPATHIES; HUMANS; MOTOR NEURON DISEASE; MUSCULAR ATROPHY, SPINAL; RECEPTORS, ANDROGEN; TRINUCLEOTIDE REPEATS;

EID: 0242475044     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/14660820310011287     Document Type: Review

References (84)

1. Hudson AJ, Kiernan JA, Munoz DG et al. Clinicopathological features of primary lateral sclerosis are different from amyotrophic lateral sclerosis. Brain Res Bull 1993; 30: 359-364.
2. Pringle CE, Hudson AJ, Munoz DG et al. Primary lateral sclerosis: clinical features, neuropathology and diagnostic criteria. Brain 1992; 115: 495-520.
3. Bailey-Wilson JE, Plato CC, Elston RC, Garruto RM. Potential role of an additive genetic component in the cause of amyotrophic lateral sclerosis and Parkinsonism-dementia in the Western Pacific. Am J Med Genet 1993; 45: 68-76.
4. Siddique T, Figlewicz DA, Pericak-Vance MA et al. Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic locus heterogeneity. New Engl J Med 1991; 324: 1381-1384.
5. Figlewicz DA, McInnis MG, Goto J et al. Identification of flanking markers for the familial amyotrophic lateral sclerosis gene ALS1 on chromosome 21. J Neurolo Sci 1994; 124S: 90-95.
6. Rosen DR, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
7. Orrell RW, Habgood JJ, Gardiner I et al. Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for Cu/Zn superoxide dismutase in UK families with amyotrophic lateral sclerosis. Neurology 1997; 48: 746-751.
8. Cudkowicz ME, McKenna-Yasek D, Sapp PE et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997; 41: 210-221.
9. Andersen PM, Forsgren L, Binzer M et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala Cu/Zn-superoxide dismutase mutation. Brain 1996; 119: 1153-1172.
10. Orrell RW, Habgood J, Rudge P et al. Difficulties in distinguishing sporadic from familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 810-812.
11. Figlewicz DA, Garruto RM, Krizus A et al. The Cu/Zn superoxide dismutase gene in ALS and Parkinsonism-dementia of Guam. NeuroReport 1994; 5: 557-560.
12. Orrell RW, Habgood JJ, Malaspina A et al. Clinical characteristics of SOD1 gene mutations in UK families with ALS. J Neurol Sci 1999; 169: 56-60.
13. Andersen PM, Nilsson P, Keranen ME et al. Phenotypic heterogeneity in motor neuron disease patients with Cu/Zn superoxide dismutase mutations in Scandinavia. Brain 1997; 120: 1723-1727.
14. Ince PG, Tomkins J, Slade JY et al. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J Neuropath Exp Neurology 57: 895-904.
15. Gurney ME, Pu H, Chin AY et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
16. Bruijn LI, Becher MW, Lee MK et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327-338.
17. Price DL, Wong PC, Borchelt DR et al. Amyotrophic lateral sclerosis and Alzheimer's disease. Lessons from model systems. Rev Neurol 1997; 153: 484-495.
18. Morrison BM, Morrison JH, Gordon JW. Superoxide dismutase and neurofilament transgenic models of amyotrophic lateral sclerosis. J Exp Zool 1998; 282: 32-47.
19. Gurney M, Cutting FB, Zhai P et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-157.
20. Klivenyi P, Ferrante RJ, Matthews RT et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med 1999; 5: 347-350.
21. Reinholz MM, Merkle CM, Poduslo JF. Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol 1999; 159: 204-216.
22. Hottinger AF, Fine EG, Gurney ME et al. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amotrophic lateral sclerosis. European Journal of Neuroscience 1997; 9: 1548-1551.
23. Nagano S, Ogawa Y, Yahagihara T, Sakoda S. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci Lett 1999; 265: 159-162.
24. Barneoud P, Curet O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp Neurol 1999; 155: 243-251.
25. Li M, Ona VO, Guegan C et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000; 288: 335-339.
26. Kostic V, Jackson-Lewis V, de Bilbao et al. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997; 277: 559-562.
27. Mohajeri MH, Figlewicz DA, Bohn MC. Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motor neuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum Gene Ther 1999; 10: 1853-1866.
28. Azzouz M, Hottinger A, Paterna JC et al. Increased motor neuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of adeno-associated virus encoding Bcl-2. Hum Mol Genet 2000; 9: 803-811.
29. Lacomblez L, Bensimon G, Leigh PN et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-1431.
30. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis ALS/motor neuron disease (MND) (Cochrane Review). In: The Cochrane Library, issue 2, 2000. Oxford: Update Software.
31. Cleveland DW. From Charcot to SOD1: Mechanisms of selective motor neuron death in ALS. Neuron 1999; 24: 515-520.
32. Rowland LP, Shneider NA. Medical Progress. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-1700.
33. Brown RH Jr, Robberecht W. Amyotrophic lateral sclerosis. Pathogenesis. Seminars Neurol 2001; 21: 131-139.
34. Shaw PJ. Mechanisms of cell death and treatment prospects in motor neuron disease. Hong Kong Med J 2001; 7: 267-280.
35. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nature Neurosci Rev 2001; 2: 806-819.
36. Rothstein JD, Vankammen M, Levey AI et al. Selective loss of glial glutamate transporter Glt-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38: 73-84.
37. Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci 1996; 16: 4069-4079.
38. Williams TL, Day NC, Ince PG et al. Calcium-permeable AMPA receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1997; 42: 200-207.
39. Carriedo SG, Yin HZ, Sensi SL, Weiss JH. Rapid Ca entry through Ca-permeable AMPA/kainate channels triggers marked intracellular Ca rises and consequent oxygen radical production. J Neurosci 1998; 18: 7727-7738.
40. Siklos L, Engelhardt JI, Alexianu ME et al. Intracellular calcium parallels motor neuron degeneration in SOD1 mutant mice. J Neuropathol Exp Neurol 1998; 57: 571-587.
41. Roy J, Minotti S, Dong L et al. Glutamate potentiates the toxicity of mutant Cu/Zn -superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. J Neurosci 1998; 18: 9673-9684.
42. Kruman II, Pedersen WA, Springer JE, Mattson MP. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol 1999; 160: 28-39.
43. Hosler BA, Sapp PC, Berger R et al. Refined mapping and characterization of the recessive familial amyotrophic lateral sclerosis locus on chromosome 2q33. Neurogenetics 1998; 2: 34-42.
44. Hadano S, Hand CK, Osuga H et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nature Genet 2001; 29: 166-173.
45. Yang Y, Hentati A, Deng H-X et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nature Genet 2001; 29: 160-165.
46. Hand CK, Khoris J, Salachas F et al. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet 2002; 70: 251-256.
47. Abalkhail A, Mitchell J, Habgood J et al. A new familial Amyotrophic Lateral Sclerosis Locus on Chromosome 16q12.1-16q12.2. Am J Hum Genet 2003; 73: 383-389.
48. Ruddy DM, Parton MJ, Al-Chalabi A et al. Two families with familial Amyotrophic Lateral Sclerosis are linked to a novel locus on chromosome 16q. Am J Hum Genet 2003; 73: 390-396.
49. Sapp PC, Hosler BA, McKenna-Yasek D et al. Identification of two novel loci for dominantly inherited familial Amyotrophic Lateral Sclerosis. Am J Hum Genet 2003; 73: 397-403.
50. Chance PF, Rabin BA, Ryan SC et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 1998; 62: 633-640.
51. Hentati A, Ouahchi K, Pericak-Vance MA et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22. Neurogenetics 1998; 2: 55-60.
52. Hosler BA, Siddique T, Sapp PC et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000; 284: 1664-1669.
53. Hutton M, Lendon CL, Rizzu P et al. Association of missense and 5-prime splice site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-705.
54. Parboosingh JS, Rouleau GA, Meninger V et al. Absence of mutations in the Mn superoxide dimutase or catalase genes in familial amyotrophic lateral sclerosis. Neuromusc Disord 1995; 5: 7-10.
55. Figlewicz DA, Krizus A, Martinoli MG et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3: 1757-1761.
56. Al-Chalabi A, Andersen PM, Nilsson P et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Molec Genet 1999; 8: 157-164.
57. Beaulieu J-M, Nguyen MD, Julien J-P. Late onset death of motor neurons in mice overexpressing wild-type peripherin. J Cell Biol 1999; 147: 531-544.
58. Lin CLG, Bristol LA, Jin L et al. Aberrant RNA processing in a neurodegenerative disease: a common cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20: 589-602.
59. Nagai M, Abe K, Okamoto K, Itoyama Y. Identification of alternative splicing forms of GLT-1 mRNA in the spinal cord of amyotrophic lateral sclerosis patients. Neurosci Lett 1998; 244: 165-168.
60. Meyer T, Fromm A, Munch C et al. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. Neurol Sci 1999; 170: 45-50.
61. Al-Chalabi A, Enayat ZE, Bakker MC et al. Association of apolipoprotein E epsilon 4 allele with bulbar onset motor neuron disease. Lancet 1996; 347: 159-160.
62. Comi GP, Bordoni A, Salani S et al. Cytochrome c oxidase subunit 1 microdeletion in a patient with motor neuron disease. Ann Neurol 1998; 43: 110-116.
63. Jackson M, Morrison KE, Al-Chalabi A et al. Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis: homozygous NAIP deletion in a sporadic case. Ann Neurol 1996; 39: 796-800.
64. Olkowski ZL. Mutant AP endonuclease in patients with amyotrophic lateral sclerosis. Neuroreport 1998; 9: 239-242.
65. Hayward C, Colville S, Swingler RJ, Brock DJH. Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis. Neurology 1999; 52: 1899-1901.
66. Mitsumoto H, Sliman RJ, Schafer IA et al. Motor neuron disease and adult hexosaminidase A deficiency in two families: evidence for multisystem degeneration. Ann Neurol 1995; 17: 378-385.
67. Myerowitz R. Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene. Hum Mutat 1997; 9: 195-208.
68. Merry DE, Kobayashi Y, Bailey CK et al. Cleavage, aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy. Hum Mol Genet 1998; 7: 693-701.
69. Doyu M, Sobue G, Muaki E et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with the size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 1992; 32: 707-710.
70. Garofalo O, Figlewicz DA, Leigh PN et al. Androgen receptor gene polymorphisms in amyotrophic lateral sclerosis. Neuromusc Disord 1993; 3: 195-199.
71. Parboosingh JS, Figlewicz DA, Krizus A et al. Spinobulbar muscular atrophy can mimic ALS: the importance of genetic testing in male patients with atypical ALS. Neurology 1997; 49: 568-572.
72. Figlewicz DA, Bird TD. "Pure" hereditary spastic paraplegias: the story becomes complicated. Neurology 1999; 53: 5-7.
73. Seri M, Cusano R, Forabosco P et al. Genetic mapping to 10q23.3-q24.2, in a large Italian pedigree, of a new syndrome showing bilateral cataracts, gastroesophageal reflux, and spastic paraparesis with amyotrophy. Am J Hum Genet 1999; 64: 586-593.
74. Reid E, Dearlove AM, Rhodes M, Rubinsztein DC. A new locus for autosomal dominant pure hereditary spastic paraplegia mapping to chromosome 12q13, and evidence for further genetic heterogeneity. Am J Hum Genet 1999; 65: 757-763.
75. Reid E, Dearlove AM, Osborn O et al. A locus for autosomal dominant pure hereditary spastic paraplegia maps to chromosome 19q13. Am J Hum Genet 2000; 66: 728-732.
76. Fontaine B, Davoine CS, Durr A et al. A new locus for autosomal dominant pure spastic paraplegia on chromosome 2q24-q34. Am J Hum Genet 2000; 66: 702-707.
77. Vazza C, Zortea M, Boaretto F et al. A new locus for autosomal recessive spastic paraplegia associated with mental retardation and distal motor neuropathy, SPG 14, maps to chromosome 3q27-q28. Am J Hum Genet 2000; 67: 504-509.
78. Hughes CA, Byrne PC, Webb S et al. SPG 15, a new locus for autosomal recessive complicated HSP on chromosome 14q. Neurology 2001; 56: 1230-1233.
79. Tamagaki A, Shima M, Tomita R et al. Segregation of a pure form of spastic paraplegia and NOR insertion into Xq11.2. Am J Med Genet 2000; 94: 5-8.
80. Patel H, Hart PE, Warner TT et al. The Silver syndrome variant of hereditary spastic paraplegia maps to chromosome 11q12-q14, with evidence for genetic heterogeneity within this subtype. Am J Hum Genet 2001; 69: 209-215.
81. Zhao X, Alvarado D, Rainier S et al. Mutations in a newly identified GTPase gene cause autosomal dominant hereditary spastic paraplegia. Nature Genet 2001; 29: 326-331.
82. Hazan J, Fonknechten N, Mavael D et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nature Genetics 1999; 23: 296-303.
83. Casari G, De Fusco M, Ciarmatori S et al. A spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 1998; 93: 973-983.
84. Auer-Grumbach M, Loscher WN, Wagner K et al. Phenotypic and genotypic heterogeneity in hereditary motor neuronopathy type V. Brain 2000; 123: 1612-1623.